Revolution not evolution of Biologics production
Stepping up to meet patient need and market demand. Streamlining, enhancing and integrating upstream and downstream biological and vaccine production. Delivering more efficient and flexible production to dynamically address the demand side
FACILITATED BY
LUCY FOLEY | Director of Biologics | CPI
PANELLISTS INCLUDE
JONATHAN HAIGH | Vice President, Process Development | FUJIFILM Diosynth Biotechnologies
MARK PROCTOR CBE | General Manager R&D and Operations | AstraZeneca
JAMES MISKIN | Chief Technical Officer | Oxford Biomedica
JAMIE UNWIN | Commercial Insight Officer | Nanoform
PAUL DALBY | Co-Director | Future Targeted Healthcare Manufacturing Hub